Aurinia Closes Equity Financing

Aurinia Pharmaceuticals Inc said late Wednesday that it has closed its previously announced sale of nearly 12.8 million units at a price of $2.25 per unit for total proceeds of $28.8 million.

Each unit consists of one common share of the company and one-half of one common share purchase warrant, entitling the holder to purchase one share at the exercise price of $3.00 per share for a period of 5 years after the closing of the offering.

By Travis Berry